skip to Main Content

Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer’s Disease


Brief Summary:

The purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813
in early symptomatic Alzheimer’s disease.


Inclusion Criteria:

– Gradual and progressive change in memory function reported by participants or
informants for ≥ 6 months.

– MMSE score of 20 to 28 (inclusive) at baseline or an acceptable historical
flortaucipir PET scan within 6 months prior to baseline that meets the central read

– Meet 18F flortaucipir PET scan criteria.

– Meet 18F florbetapir PET scan (central read) criteria.

Exclusion Criteria:

– Have a history of long QT syndrome.

– Have received treatment with a stable dose of an acetylcholinesterase inhibitor
(AChEI) and/or memantine for less than 2 months before randomization.

– Contraindication to MRI.


  • Neurology Center of North Orange County, Fullerton, California, United States, 92835
  • Irvine Clinical Research Center, Irvine, California, United States, 92614
  • Institute for Memory Impairment & Neurological Disorders, Irvine, California, United States, 92697
  • Pharmacology Research Institute, Newport Beach, California, United States, 92660
  • Pacific Research Network Inc, San Diego, California, United States, 92103
  • Sharp Mesa Vista Hospital, San Diego, California, United States, 92123
  • Syrentis Clinical Research, Santa Ana, California, United States, 92705
Back To Top